EUVIMEDEUVIMED entdecken
Open Access

Physiologically Based Pharmacokinetic Modelling in Critically Ill Children Receiving Anakinra While on Extracorporeal Life Support

Samuel Dubinsky, Abdullah Hamadeh, Carina Imburgia, Autumn McKnite, J Porter Hunt, Kristy Wong, Cassandra Rice, Joseph Rower, Kevin Watt, Andrea Edginton iD

Clinical Pharmacokinetics · 2024

DOI: 10.1007/s40262-024-01424-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacokinetics, 2024. Verfasst von Samuel Dubinsky und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Faculty of Science, University of Waterloo, Waterloo, ON, Canada. Hauptthemen laut MEDLINE: Interleukin 1 Receptor Antagonist Protein, Critical Illness, Extracorporeal Membrane Oxygenation, Models, Biological. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS, Foundation for the National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVE: Because of the pathophysiological changes associated with critical illness and the use of extracorporeal life support (ECLS) such as continuous renal replacement therapy (CRRT) and extracorporeal membrane oxygenation (ECMO), the pharmacokinetics of drugs are often altered. The objective of this study was to develop a physiologically based pharmacokinetic (PBPK) model for anakinra in children that accounts for the physiological changes associated with critical illness and ECLS technology to guide appropriate pharmacotherapy. METHODS: A PBPK model for anakinra was first developed in healthy individuals prior to extrapolating to critically ill children receiving ECLS. To account for the impact of anakinra clearance by the dialysis circuit, a CRRT compartment was added to the pediatric PBPK model and parameterized using data from a previously published ex-vivo study. Additionally, an ECMO compartment was added to the whole-body structure to create the final anakinra ECLS-PBPK model. The final model structure was validated by comparing predicted concentrations with observed patient data. Due to limited information in guiding anakinra dosing in this population, in-silico dose simulations were conducted to provide baseline recommendations. RESULTS: By accounting for changes in physiology and the addition of ECLS compartments, the final ECLS-PBPK model predicted the observed plasma concentrations in an adolescent receiving subcutaneous anakinra. Furthermore, dosing simulations suggest that anakinra exposure in adolescents receiving ECLS is similar to that in healthy counterparts. CONCLUSION: The anakinra ECLS-PBPK model developed in this study is the first to predict plasma concentrations in a population receiving simultaneous CRRT and ECMO. Dosing simulations provided may be used to inform anakinra use in critically ill children and guide future clinical trial planning.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin 1 Receptor Antagonist ProteinCritical IllnessExtracorporeal Membrane OxygenationModels, BiologicalHumansChildChild, PreschoolAdolescentMaleFemaleInfantContinuous Renal Replacement TherapyComputer Simulation

Substanzen

Interleukin 1 Receptor Antagonist Protein

Autor:innen und Institutionen

  • School of Pharmacy, Faculty of Science, University of Waterloo, Waterloo, ON, Canada.
  • Department of Pediatrics, School of Medicine, University of Utah, Salt Lake City, UT, USA.
  • Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT, USA.
  • Center for Human Toxicology, University of Utah, Salt Lake City, UT, USA.
  • School of Pharmacy, Faculty of Science, University of Waterloo, Waterloo, ON, Canada. aedginto@uwaterloo.ca.

ORCID-Profile: Andrea Edginton

Förderung

  • NICHD NIH HHS
  • Foundation for the National Institutes of Health

Zitieren

APA

Dubinsky, S., Hamadeh, A., Imburgia, C., McKnite, A., Porter Hunt, J., Wong, K., Rice, C., Rower, J., Watt, K., & Edginton, A. (2024). Physiologically Based Pharmacokinetic Modelling in Critically Ill Children Receiving Anakinra While on Extracorporeal Life Support. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-024-01424-w

Vancouver

Dubinsky S, Hamadeh A, Imburgia C, McKnite A, Porter Hunt J, Wong K, et al. Physiologically Based Pharmacokinetic Modelling in Critically Ill Children Receiving Anakinra While on Extracorporeal Life Support. Clinical Pharmacokinetics. 2024. doi:10.1007/s40262-024-01424-w

BibTeX
@article{Dubinsky2024,
  author = {Dubinsky, Samuel and Hamadeh, Abdullah and Imburgia, Carina and McKnite, Autumn and Porter Hunt, J and Wong, Kristy and Rice, Cassandra and Rower, Joseph and Watt, Kevin and Edginton, Andrea},
  title = {Physiologically Based Pharmacokinetic Modelling in Critically Ill Children Receiving Anakinra While on Extracorporeal Life Support},
  journal = {Clinical Pharmacokinetics},
  year = {2024},
  doi = {10.1007/s40262-024-01424-w}
}
Kostenlos starten →